<DOC>
	<DOCNO>NCT02071641</DOCNO>
	<brief_summary>Targeted therapy associate ( acquire ) resistance median 5-11 month treatment , result disease progression , almost tumor intrinsically resistant first line setting . The investigator recently publish tumor cell resistance sunitinib may directly relate lysosomal sequestration sunitinib . This resistance mechanism show transient , since drug-free culture period could normalize lysosomal storage capacity sunitinib result recovery drug sensitivity . In two report suggest patient metastatic Renal Cell Carcinoma respond sunitinib first-line setting may benefit rechallenge sunitinib failure second-line treatment . However , data retrospective . A prospective trial investigate rechallenge sunitinib need determine whether strategy benefit patient mRCC prior clinical benefit sunitinib stop treatment overt clinical resistance .</brief_summary>
	<brief_title>Phase II Study Sunitinib Rechallenge Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm clearcell mRCC . 2 . Patients progressed firstline treatment sunitinib clinical benefit define response ( accord Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 criterion ) SD 6 month treatment . 3 . Patients progressed secondline treatment ( mTOR inhibitor treatment long patient treat Vascular Endothelial Growth Factor ( VEGF ) target Tyrosine Kinase Inhibitor ( TKI ) , see exclusion criterion ) , progress treatmentfree interval least 3 month since discontinuation firstline sunitinib treatment . 4 . Patients radiological ( and/or clinical ) confirm progressive disease accord RECIST 1.1 criterion . 5 . Measurable evaluable disease define RECIST 1.1 . 6. WHO performance status 02 . 7 . Life expectancy least 12 week . 8 . Age 18 year old . 9 . Able receive oral medication . 10 . Able provide write informed consent . 11 . Adequate hematologic function : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , Hb ≥ 6.0 mmol/L . 12 . Patients brain metastasis eligible stable least two month postradiation therapy surgery . 13 . No current malignant disease , except basal cell carcinoma skin . 14 . Adequate hepatic function : serum bilirubin ≤ 1.5 x Upper Limit Normal ( ULN ) , Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) ≤ 2.5 x ULN ( ≤ 5 time ULN liver metastasis present ) . 15 . Renal function : estimate glomerular filtration rate ≥ 40 ml/min . 16 . Patients reproductive potential must use effective contraception . Female patient must negative pregnancy test . 1 . Patients treat VEGF target TKI ( sorafenib , pazopanib , axitinib , dovitinib ) secondline treatment progression firstline sunitinib treatment . 2 . Uncontrolled hypertension . Blood pressure must ≤160/95 mmHg time screen stable antihypertensive regimen . Blood pressure must stable least 2 separate measurement least 2 separate day . 3 . Active infection serious intercurrent illness . 4 . Presence unstable angina , recent myocardial infarction ( within previous 3 month ) . 5 . Macroscopic hematuria . 6 . Presence significant central nervous system psychiatric disorder ( ) would hamper patient 's compliance . 7 . Any major illness , investigator 's judgment , substantially increase risk associate subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>